Skip to main content
. Author manuscript; available in PMC: 2026 Oct 13.
Published in final edited form as: Lancet. 2026 May 30;407(10544):2217–2226. doi: 10.1016/S0140-6736(26)00417-4

Figure 3: [18F]Flortaucipir and [18F]MK6240 tau positivity as a function of amyloid-β burden.

Figure 3:

(A) Probability of tau positivity in the MTL and neocortex for [18F]flortaucipir and [18F]MK6240, and probability of memory impairment, as a function of Aβ burden (Centiloid). (B) Centiloid thresholds for 50% probability of tau positivity with each tracer and for 50% probability of decline in memory, executive function, attention, language, and visuospatial function. Shaded areas represent 95% CI. Aβ=amyloid-β. MTL=medial temporal lobe. Neo=neocortex.